Form 4: ADMA Biologics CEO Adam Grossman Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Adam Grossman, President and CEO of ADMA Biologics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 15, 2025, Adam Grossman, the President and CEO of ADMA Biologics, exercised a stock option to acquire 15,000 shares of common stock at a price of $5.40 per share.
- Simultaneously, Grossman sold 15,000 shares at $19.45 per share and an additional 6,000 shares at $19.45 per share.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on December 5, 2024.
- Following these transactions, Grossman directly owns 2,049,850 shares of ADMA Biologics common stock.
- Grossman also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
- He also holds options to purchase 825,950 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests that these transactions were pre-planned and not based on any material non-public information. Investors often monitor such filings for insights into management's view of the company's prospects, but pre-planned sales are generally viewed as less informative.
Comparison to Industry Standards
- Insider trading activity is common across publicly listed companies, particularly in the biotechnology sector where stock options form a significant part of executive compensation.
- Companies like Amgen, Gilead Sciences, and Regeneron regularly report Form 4 filings from their executives.
- The use of 10b5-1 plans is a standard practice to avoid accusations of trading on insider information, aligning with best practices in corporate governance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates concerns about insider information being used.
- Employees are unlikely to be directly affected by these transactions.
Key Dates
| Date | Description |
|---|---|
| 2024-12-05 | Date of establishment of Rule 10b5-1 trading plan |
| 2025-02-19 | Date of grant of 252,022 unvested RSUs |
| 2025-02-26 | Date of grant of 418,296 unvested RSUs and stock option |
| 2025-03-06 | Date of grant of 286,848 unvested RSUs |
| 2025-03-07 | Date of grant of 75,000 unvested RSUs |
| 2025-05-15 | Date of stock option exercise and share sales |
| 2034-02-26 | Expiration date of stock option |
Keywords
ADMA Biologics, Adam Grossman, stock options, share sale, Rule 10b5-1, insider trading, securities, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.